Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /homepages/27/d24994768/htdocs/clickandbuilds/WordPress/wptest/wp-content/plugins/types/library/toolset/types/embedded/includes/wpml.php on line 643

Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /homepages/27/d24994768/htdocs/clickandbuilds/WordPress/wptest/wp-content/plugins/types/library/toolset/types/embedded/includes/wpml.php on line 660

Warning: session_start(): Cannot start session when headers already sent in /homepages/27/d24994768/htdocs/clickandbuilds/WordPress/wptest/wp-content/themes/Divi/header.php on line 1
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury | Inventages

AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury


Bunnik, The Netherlands, March 9th 2018. AM‐Pharma B.V., an Inventages portfolio company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney Injury (AKI), the largest therapeutic study in AKI to date.

Professor Peter Pickkers, MD PhD, Chair of Experimental Intensive Care Medicine, Radboud University Medical Center, and principal investigator of the STOP-AKI study said: “Acute Kidney Injury affects millions of patients each year and comes with a substantial risk of mortality. The significant improvements demonstrated in survival and kidney function are very encouraging and strongly support further development of recAP.”

The STOP-AKI study demonstrated a significant and dose-dependent relative reduction in mortality of more than 40% in the treatment group compared to the placebo group. While the addition of recAP to the standard of care did not affect kidney function in the first week of the study (the primary endpoint), it did show a significant, progressive and sustained improvement in renal function over the 28-day study period. Throughout the study, safety data were regularly reviewed by an independent Data Safety Monitoring Board (DSMB), without any observations of concern.

The STOP-AKI data will be presented today by the principle investigator Professor Pickkers at the AKI & CRRT conference in San Diego and at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) on March 21st in Brussels.

Previously, the US Food and Drug Administration granted Fast Track designation to recAP for the treatment of sepsis-associated acute kidney injury. Acute Kidney Injury involves inflammatory processes in the kidney which can lead to complete loss of renal function and is associated with high mortality rates.

Erik van den Berg, CEO of AM-Pharma said: “We are delighted with the outcomes of our STOP-AKI Phase II study. This is a major advance in the development of recAP, which could have a significant impact on patients with Acute Kidney Injury, for whom there is currently no treatment available. We are grateful to the patients, their families and the dedicated medical teams who contributed to this study”.

“Acute Kidney Injury is a common complication of sepsis in ICU patients,” said John A. Kellum, MD, Professor and Vice Chair Department of Critical Care Medicine and Director, Center for Critical Care Nephrology at University of Pittsburgh. “These fascinating data from the STOP-AKI trial show the drug’s potential to prevent patients dying from this serious and devastating condition.” 

Company contact: 
Erik van den Berg (CEO)
+31 30 259 8838

Media contact: 
80th Atom
Adam Michael
+44 1223 51 1338
+44 777 588 1813

Notes to Editors

About AM-Pharma www.am-pharma.com

AM‐Pharma is a biopharmaceutical company focused on the development of recAP (recombinant Human Alkaline Phosphatase) for treatment of Acute Kidney Injury (AKI), Ulcerative Colitis (UC), and Hypophosphatasia (HPP). Based on strong results from Phase II trials with bovine Alkaline Phosphatase in AKI and UC, AM‐Pharma has developed an innovative recombinant form of human Alkaline Phosphatase (recAP), and recently completed recruitment of 301 patients in the STOP-AKI adaptive Phase II trial for sepsis-associated AKI. In May 2015, AM-Pharma entered an agreement with Pfizer. Under the terms of the agreement, Pfizer made an upfront payment of $87.5 million for a minority equity interest, and obtained an exclusive option to acquire the Company, with additional potential payments of up to $512.5 million upon option exercise and potential launch of any product that may result from the agreement.